Statin treatment for primary prevention of vascular disease: Whom to treat? Cost-effectiveness analysis

BMJ

Volumn 342, Issue 7801, 2011, Pages

  Greving, J P ^a   Visseren, F L J ^a   De Wit, G A ^a,b   Algra, A ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; FATALITY; FEMALE; HEALTH CARE COST; HEART INFARCTION; HIDDEN MARKOV MODEL; HUMAN; LOW DRUG DOSE; MALE; MONTE CARLO METHOD; MYOPATHY; NETHERLANDS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHABDOMYOLYSIS; SENSITIVITY ANALYSIS; STROKE; TREATMENT OUTCOME; VASCULAR DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; MORTALITY; PROBABILITY;

AGED; COST-BENEFIT ANALYSIS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; STROKE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79953906771     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1672     Document Type: Article

References (45)

1. Vaartjes I, Reitsma JB, de Bruin A, Berger-van Sijl M, Bos MJ, Breteler MM, et al. Nationwide incidence of first stroke and TIA in the Netherlands. Eur J Neurol 2008;15:1315-23.
2. American Heart Association. Heart disease and stroke statistics-2008 update. 2008. www.americanheart.org/downloadable/heart/1200082005246HS- Stats%202008.final.pdf.
3. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
4. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6. (Pubitemid 30013066)
5. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81.
6. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a metaanalysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13. (Pubitemid 44833354)
7. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ 2009;338:b2376.
8. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-31.
9. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10:2973-85.
10. Perreault S, Ellia L, Dragomir A, Cote R, Blais L, Berard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am JMed 2009;122:647-55.
11. Christie B. Guidelines on treating risk factors turn healthy people into patients, doctors say. BMJ2006;333:988.
12. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008;117:2875-83. (Pubitemid 351787070)
13. Huse DM, Russell MW, Miller JD, Kraemer DF, D'Agostino RB, Ellison RC, et al. Cost-effectiveness of statins. Am J Cardiol 1998;82:1357-63. (Pubitemid 28565322)
14. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32. (Pubitemid 29429605)
15. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132:769-79. (Pubitemid 30317791)
16. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001;22:919-25. (Pubitemid 32625214)
17. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-36. (Pubitemid 46768187)
18. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-iv.
19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38. (Pubitemid 24013155)
21. Koek H, de Bruin A, Gast A, Gevers E, Kardaun J, Reitsma J, et al. Incidence of first acute myocardial infarction in the Netherlands. Neth J Med 2007;65:434-41.
22. Jager-Geurts MH, Peters RJG, van Dis SJ, Bots ML. Cardiovascular diseases in The Netherlands 2006. Figures on risk factors, morbidity and mortality. Netherlands Heart Foundation, 2006.
23. Koek H, de Bruin A, Gast F, Gevers E, Kardaun JW, Reitsma JB, et al. Short-and long-term prognosis after acute myocardial infarction in men versus women. Am J Cardiol 2006;98:993-9. (Pubitemid 44486133)
24. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52-60C.
25. Statistics Netherlands. Lifetables: Dutch population by age and sex, 1996-2000. Statistics Netherlands, 2002.
26. Bronnum-Hansen H, JorgensenT, DavidsenM, MadsenM, Osler M, Gerdes LU, et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol 2001;54:1244-50. (Pubitemid 34002977)
27. Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural historyof prevalent ischaemic heart disease in middle-aged men. Eur Heart J 2000;21:1052-62. (Pubitemid 30352989)
28. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001;32:2131-6. (Pubitemid 32868112)
29. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796-800. (Pubitemid 23163551)
30. Wolfe CD. The impact of stroke. Br Med Bull 2000;56:275-86.
31. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SY, Kettunen R, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther 2008;30:2228-40.
32. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62. (Pubitemid 28228203)
33. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999;5:437-44. (Pubitemid 29202923)
34. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-5. (Pubitemid 23113453)
35. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001;32:1425-9. (Pubitemid 32530435)
36. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med 1998;13:824-35. (Pubitemid 29009294)
37. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 1992;12:239-49.
38. Dutch Health Care Insurance Board. Drugcosts. 2009. www. medicijnkosten.nl.
39. Dutch Healthcare Authority. Rates for various professionals and various laboratory tests. 2009. www.nza.nl.
40. De Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JC, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am JCardiol 1995;76:830-3.
41. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6. (Pubitemid 27057183)
42. Buskens E, Nederkoorn PJ, Buijs-van der Woude T, Mali WP, Kappelle LJ, Eikelboom BC, et al. Imaging of carotid arteries in symptomatic patients: cost-effectiveness of diagnostic strategies. Radiology 2004;233:101-12. (Pubitemid 39280963)
43. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Guideline for costing research. Methods and standardized prices for economic evaluations in health care. Health Care Insurance Board (The Netherlands), 2004.
44. Stolk E, Krabbe P, Busschbach J. Using the Internet to collect EQ-5D norm scores: a valid alternative? Proceedings of the Plenary Meeting of the Euro Qol Group 2007;153:65.
45. Grover SA, HoV, Lavoie F, Coupal L, Zowall H, Pilote L.The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 2003;163:333-9. (Pubitemid 36183862)